Recruiting

Chardonnay Marc

Sponsor:

UCLA

Code:

NCT06476795

Conditions

Cardiovascular Diseases

Adiposity

Cardiometabolic Syndrome

Eligibility Criteria

Sex: Female

Age: 45 - 70

Healthy Volunteers: Accepted

Interventions

Chardonnay Marc

Study Details

Brief summary:

Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.

Conditions

Cardiovascular Diseases

Adiposity

Cardiometabolic Syndrome

Study ID

NCT06476795

Start date

Jun 1, 2024

Status verified date

Aug, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 45 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Postmenopausal female, with a cessation of menses for at least 2 years
  • 45-70 years of age
  • BMI 25- 49.9 kg/m2
  • Fasting triglycerides > 120 mg/dL
  • Subject is willing and able to comply with the study protocols and procedures.

Exclusion Criteria:

  • Self-reported use of daily anticoagulation agents including aspirin, NSAIDs
  • Prescription medications and supplements, except for a 6 month stable dose of thyroid medications
  • Vegan, Vegetarians, food faddists or those consuming a non-traditional diet
  • Fruit consumption ≥ 3 cups/day
  • Vegetable consumption ≥ 4 cups/day
  • Coffee/tea ≥ 3 cups/day
  • Dark chocolate ≥ 3 oz/day
  • Self-reported restriction of physical activity due to a chronic health condition
  • Self-reported chronic/routine high intensity exercise
  • Blood pressure ≥ 140/90 mm Hg
  • Self-reported renal or liver disease
  • Self-reported heart disease, which includes cardiovascular events and stroke, diabetes
  • Peripheral artery disease Raynaud's syndrome or disease
  • Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
  • Self-reported cancer within past 5 years
  • Self-reported gastrointestinal disorders, apart from appendix removal
  • Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment.
  • Indications of substance or alcohol abuse within the last 3 years
  • All forms of smoking (e.g. vaping, cigarette, cannabis)
  • Current enrollee in a clinical research study.

Study Design

Enrollment

5 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Chardonnay Marc Intake Level 1

Daily intake of Chardonnay marc at 1.5 g

experimental: Chardonnay Marc Intake Level 2

Daily intake of Chardonnay marc at 4.5 g

Interventions

Chardonnay Marc

Food product made from Chardonnay wine grapes

Primary outcome measure

  • Microvascular function [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Roberta R Holt, PhD

5304005952rrholt@ucdavis.edu

Locations

University of California, Davis

Recruiting

Davis, California, United States, 95616

Contacts

Roberta Holt, PhD

530-400-5952rrholt@ucdavis.edu

More Information

Sponsor

University of California, Davis

Last update posted

Aug 7, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Davis on 2026-08-07.